RxDoctor Payments Data

Venugopal Vatsavayi, MD

Psychiatry · Baton Rouge, LANPI 1659318442

Payments from drug & device makers

$2,974in general payments, 2019–2025

Across 234 payments — averaging $12.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$555
  • Johnson & Johnson$474
  • Takeda Pharmaceuticals U.S.A., Inc.$394
  • Otsuka America Pharmaceutical, Inc.$330
  • Sunovion Pharmaceuticals Inc.$222
  • Lundbeck LLC$196
  • plus $804 from 12 others

What the payments were for

  • Food & beverage$2,85396%
  • Education$1214%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,974 in reported general payments places this provider in the 80th percentile of 474 psychiatry providers in Louisiana.

See all psychiatry providers in Louisiana

Medicare billing

Part B allowed, 2024
$177,055
Medicare patients
313
Services billed
2,105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate55$119,781
IngrezzaValbenazine Tosylate12$102,467
RexultiBrexpiprazole43$88,580
VraylarCariprazine Hcl26$36,492
TrintellixVortioxetine Hydrobromide14$10,937
VyvanseLisdexamfetamine Dimesylate27$10,344
Bupropion XlBupropion Hcl269$9,041
ViibrydVilazodone Hcl15$8,958
Quetiapine Fumarate425$6,773
Aripiprazole177$5,650
BelsomraSuvorexant13$5,433
Desvenlafaxine Succinate ErDesvenlafaxine Succinate114$5,388
Quetiapine Fumarate ErQuetiapine Fumarate20$4,401
Asenapine Maleate19$3,680
Dextroamphetamine Sulfate18$3,425

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$474$119,78155 claims
Neurocrine Biosciences, Inc.Ingrezza$118$102,46712 claims
Otsuka America Pharmaceutical, Inc.Rexulti$330$88,58043 claims
AbbVieVraylar, Viibryd$555$45,45041 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$394$21,28141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 474 psychiatry providers in Louisiana.

Other psychiatry in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →